[go: up one dir, main page]

BRPI0520167A2 - formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero - Google Patents

formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Info

Publication number
BRPI0520167A2
BRPI0520167A2 BRPI0520167-5A BRPI0520167A BRPI0520167A2 BR PI0520167 A2 BRPI0520167 A2 BR PI0520167A2 BR PI0520167 A BRPI0520167 A BR PI0520167A BR PI0520167 A2 BRPI0520167 A2 BR PI0520167A2
Authority
BR
Brazil
Prior art keywords
menthol
mixture
poloxamer
peg
surfactant mixture
Prior art date
Application number
BRPI0520167-5A
Other languages
English (en)
Inventor
Moshe Flashner-Barak
E Itzhak Lerner
Vered Rosenberger
Noami Moldavski
Original Assignee
Teva Pharmaceutical Ind Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Ind Ltda filed Critical Teva Pharmaceutical Ind Ltda
Publication of BRPI0520167A2 publication Critical patent/BRPI0520167A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES APRIMORADAS DE FENOFIBRATO CONTENDO MENTOL OU UMA MISTURA DE PEG/POLOXÂMERO. A invenção proporciona pelo menos uma composição para o tratamento de níveis elevados de triglicérides, consistindo de uma quantidade terapeuticaInente eficaz de fenofibrato ou outro fibrato intimamente associado ao mentol ou uma mistura surfactante, em que o mentol pode ser mentol ou mistura surfactante de mentol, e em que a mistura surfactante pode ser uma mistura de um polietileno glicol e um poloxâmero, tais como PEG (1000) e poloxâmero (407) A invenção também provê um método para o tratamento de níveis elevados de triglicérides em um sujeito, que consiste em administrar ao sujeito uma composição que consiste de uma quantidade terapeuticamente efetiva de fenofibrato ou outro fibrato e mentol ou uma mistura surfactante, em que o fenofibrato ou o outro fibrato está em associação intima com o mentol ou mistura surfactante, em que o mentol pode ser mentol ou mistura surfactante de mentol, e em que a mistura surfactante pode ser uma mistura de um polietileno glicol e um poloxâmero, tais como PEG (1000) e poloxâmero (407)
BRPI0520167-5A 2005-03-30 2005-12-29 formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero BRPI0520167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66619205P 2005-03-30 2005-03-30
PCT/US2005/047676 WO2006107357A1 (en) 2005-03-30 2005-12-29 Improved formulations of fenofibrate containing menthol or a peg/poloxamer mixture

Publications (1)

Publication Number Publication Date
BRPI0520167A2 true BRPI0520167A2 (pt) 2009-04-22

Family

ID=35058530

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0520138-1A BRPI0520138A2 (pt) 2005-03-30 2005-07-18 formulações aprimoradas de fenofibrato contendo mentol ou peg/poloxámero
BRPI0520167-5A BRPI0520167A2 (pt) 2005-03-30 2005-12-29 formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0520138-1A BRPI0520138A2 (pt) 2005-03-30 2005-07-18 formulações aprimoradas de fenofibrato contendo mentol ou peg/poloxámero

Country Status (12)

Country Link
US (1) US20060222706A1 (pt)
EP (2) EP1861084A1 (pt)
JP (2) JP2008505934A (pt)
KR (2) KR20070113289A (pt)
CN (3) CN101212962A (pt)
AU (2) AU2005330266A1 (pt)
BR (2) BRPI0520138A2 (pt)
CA (2) CA2601372A1 (pt)
EA (2) EA200701750A1 (pt)
IL (2) IL185734A0 (pt)
MX (2) MX2007011858A (pt)
WO (2) WO2006107316A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US7915247B1 (en) 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
WO2008104852A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions comprising adsorbate of fenofibrate
US20100209495A1 (en) * 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
US8632846B2 (en) * 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US9849184B2 (en) * 2011-12-14 2017-12-26 Lts Lohmann Therapie-Systeme Ag Wafer and capsule formulations with enhanced dissolution rates for fenofibrate
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US20030153585A1 (en) * 2000-01-13 2003-08-14 Sven-Alexander Schreder Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
EP1322289B1 (en) * 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
ES2334991T3 (es) * 2002-03-26 2010-03-18 Teva Pharmaceutical Industries Ltd. Microparticulas de farmaco.
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
JP2006524190A (ja) * 2003-02-20 2006-10-26 テバ ファーマシューティカル インダストリーズ リミティド 薬剤のメントール溶液
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US7658944B2 (en) * 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin

Also Published As

Publication number Publication date
CN101212962A (zh) 2008-07-02
US20060222706A1 (en) 2006-10-05
CA2601374A1 (en) 2006-10-12
KR20070113289A (ko) 2007-11-28
IL185734A0 (en) 2008-01-06
JP2008505934A (ja) 2008-02-28
WO2006107357A1 (en) 2006-10-12
AU2005330266A1 (en) 2006-10-12
AU2005330320A1 (en) 2006-10-12
CN101217950A (zh) 2008-07-09
MX2007011858A (es) 2008-03-25
EA200701750A1 (ru) 2008-02-28
WO2006107316A1 (en) 2006-10-12
IL185735A0 (en) 2008-01-06
EP1707196A1 (en) 2006-10-04
BRPI0520138A2 (pt) 2011-04-19
EA200701986A1 (ru) 2008-04-28
CA2601372A1 (en) 2006-10-12
EP1861084A1 (en) 2007-12-05
CN101217951A (zh) 2008-07-09
KR20070120990A (ko) 2007-12-26
JP2008534584A (ja) 2008-08-28
MX2007012125A (es) 2007-12-07
WO2006107316A8 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BRPI0520167A2 (pt) formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
ATE538801T1 (de) Therapeutische zusammensetzungen mit mindestens einem pyrrolobenzodiazepin-derivat und fludarabin
ECSP10010589A (es) Farmaco contra el cancer de higado
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
MX2009008022A (es) Metodos y composiciones para tratar neuropatias.
AR065138A1 (es) Uso de compuestos de arsenico para el tratamiento del dolor y la inflamacion
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
JO3598B1 (ar) الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AR063470A1 (es) Terapia combinada
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BRPI0414481A (pt) métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
EA200701751A1 (ru) Улучшенные составы фенофибрата
MX2021014561A (es) Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc.
BRPI0516077A (pt) composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes
BRPI0511707A (pt) peroxifosfatos de cálcio e sua utilização em composições dentais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2203 DE 26/03/2013.